Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): An intergroup, open-label, randomised phase 3 trial

Additional Metadata
Persistent URL	doi.org/10.1016/S1470-2045(14)71160-X, hdl.handle.net/1765/91130
Journal	The Lancet Oncology
Organisation	Erasmus MC: University Medical Center Rotterdam
Citation APA APA Style APA-ALL Style AAA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Sternberg, C., Skoneczna, I., Kerst, M., Albers, P., Fossa, S., Agerbaek, M., Dumez, H., de Santis, M., The´odore, C., Leahy, M., Chester, J. D., Verbaeys, A., Daugaard, G., Wood, L., Witjes, A., de Wit, R., Geoffrois, L., Sengelov, L., Thalmann, G., … Sylvester, R. (2015). Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): An intergroup, open-label, randomised phase 3 trial. The Lancet Oncology, 16(1), 76–86.https://doi.org/10.1016/S1470-2045(14)71160-X

Publication